Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Panel Slams MHLW’s 80% Single-IRB Target as Too Low
Members of a government regulatory reform panel on March 23 criticized the health ministry’s target for promoting single institutional review boards (IRBs), saying that the goal of covering 80% of multi-center clinical trials falls short and lacks urgency. The Ministry…
To read the full story
Related Article
- Japan Moves to Bar Duplicate IRB Reviews under Single-IRB Framework
July 23, 2026
- MHLW Official Urges Proper IRB Selection under New GCP Rules
June 12, 2026
- MHLW Pushes Back GCP Ordinance Revision to Summer
February 3, 2026
- Japan Mulls Amendment of GCP Ordinance, Making Single IRBs a Rule
April 3, 2025
- Include Single IRB Policy in GCP to Accelerate Trials: EFPIA Official
February 10, 2025
- Consolidate IRBs to Streamline Clinical Trials in Japan: Govt Working Group
March 11, 2024
REGULATORY
- Japan Enacts Revised Immunization Act, Opens Way for RSV Antibodies under NIP
July 27, 2026
- PMDA Sees Drop in Japan-China Bilateral Regulatory Exchanges
July 27, 2026
- MHLW to Hear Patient Groups on OTC-Like Drug Charge Exemptions
July 27, 2026
- Japan to Clarify Non-Clinical Data Waivers for Repurposed Drugs, Ease Sakigake Rules
July 24, 2026
- Share of Negative-Margin WPPs Rises to 6.9%, Wholesalers Cite Communication Gap
July 24, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…